Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced Systemic and Local Therapy in Oligometastatic Prostate Cancer
NCT05212857Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Abiraterone Acetate Tablets (I), apalutamide and enzalutamide in prostate cancer (PCa), sponsored by Fudan University. Primary endpoint: Radiographic Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Abiraterone Acetate Tablets (I)apalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05212857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212857.